# Ep. 308 Navigating Shared Decision-Making in Bladder Cancer Treatment with Dr. Kelly Bree, Dr. Meredith Donahue, and Dr. Saum Ghodoussipour

Page: https://stenobird.com/podcast/backtable-urology-3724776/ep-308-navigating-shared-decision-making-in-bladder-cancer-treatment-with-dr-kelly-bree-dr-meredith-donahue-and-dr-saum-ghodoussipour
Text version: https://stenobird.com/podcast/backtable-urology-3724776/ep-308-navigating-shared-decision-making-in-bladder-cancer-treatment-with-dr-kelly-bree-dr-meredith-donahue-and-dr-saum-ghodoussipour.md
Podcast: [BackTable Urology](https://stenobird.com/podcast/backtable-urology-3724776)
Published: 2026-06-11T07:00:00+00:00
Episode link: https://traffic.megaphone.fm/BTL2300007938.mp3
Audio file: https://traffic.megaphone.fm/BTL2300007938.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-308-navigating-shared-decision-making-in-bladder-cancer-treatment-with-dr-kelly-bree-dr-meredith-donahue-and-dr-saum-ghodoussipour
Duration seconds: 2903

## Resource

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Mu…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-308-navigating-shared-decision-making-in-bladder-cancer-treatment-with-dr-kelly-bree-dr-meredith-donahue-and-dr-saum-ghodoussipour/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/backtable-urology-3724776/ep-308-navigating-shared-decision-making-in-bladder-cancer-treatment-with-dr-kelly-bree-dr-meredith-donahue-and-dr-saum-ghodoussipour.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.